Hadju 1997

Methods	RCT Length of follow‐up: 12 months
Participants	All children living in endemic area Number analysed for primary outcome: 330; mean age 8.3 years Inclusion criteria: all primary school children in grades 1, 2, and 3 in 2 schools in slum areas in Indonesia; randomized according to Ascaris egg count and age Exclusion criteria: children > 11; signs of puberty; signs of severe protein energy malnutrition
Interventions	Multiple doses vs placebo Pyrantel pamoate: 10 mg/kg; Pyrantel pamoate: 10 mg/kg repeated at 6 months; Albendazole: 400 mg; Albendazole: 400 mg repeated at 6 months; Placebo.
Outcomes	Stool (Kato‐Katz) prevalence and intensity; Weight; Height; MUAC; z‐scores: weight‐for‐age, height for age, weight‐for‐height, and MUAC. Results of multivariate analysis using z‐scores presented and could not be used in meta‐analysis; unadjusted results not reported
Notes	Location: Indonesia Community category: 1 Placebo group showed an unexplained drop in egg counts at the 3‐month exam Source of funding: Directorate of Higher Education, Department of Education and Culture, Government of Indonesia through Hibah Bersaing Project I & II. Albendazole and placebo provided by Smithkline Beecham Pharmaceuticals Indonesia.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomly assigned "by sex and egg count".
Allocation concealment (selection bias)	Unclear risk	No details reported.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	No details reported.
Incomplete outcome data (attrition bias) All outcomes	High risk	65% (330/507) of randomized participants were evaluated, number lost from each treatment group not reported. Inclusion of all randomized participants (number evaluable/number randomized): 65% (330/507).
Selective reporting (reporting bias)	Low risk	All stated outcomes reported.
Other bias	Low risk	No obvious other source of bias.